Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Benitec Biopharma Limited
BNTC | US
13.18
USD-0.81
-5.79%
BNTC | US
About Benitec Biopharma Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
21/04/2026
Close
13.18
Open
13.90
High
13.90
Low
13.16
Benitec Biopharma Inc. a development-stage biotechnology company focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301 an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward California.
View LessBNTC | US
Risk
60.8
Sharpe
-0.15
Luna's Score
49/100
Recommendation
Hold
Luna says (BNTC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
67.4%1 month
60.8%3 months
58.7%6 months
67.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.25
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.27
Ent. to rev.
10.46K
PEG
-
Other Fundamentals
EBITDA
-22.40M
MarketCap
235.84M
MarketCap(USD)
235.84M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
12.50
Ret. on equity
-91.68
Short ratio
2.67
Short perc.
0.66
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
3.97
Range1M
4.38
Range3M
4.48
Volumes: Market Activity
Rel. volume
0.82
Price X volume
1.15M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.27 | - | Cheaper |
| Ent. to Revenue | 10,457.70 | - | Expensive |
| PE Ratio | - | 30.05 | - |
| Price to Book | 4.25 | 13.15 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 58.74 | - | Par |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 235.84M | - | Emerging |
